
The US government will cut the subsidies available for Biogen's controversial Alzheimer's drug, Aduhelm, and the decision is being felt on the US stock post-market on Tuesday, reports Bloomberg News.
Coverage of Aduhelm is now limited to clinical trial participants, meaning that subsidies going to regular patients on Medicare in the US will disappear.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app